Menu Search
Equities

MYND Life Sciences Inc

MYNDF:QBB

MYND Life Sciences Inc

Actions
  • Price (USD)0.0249
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MYND Life Sciences Inc. is a Canada-based medical biotech drug research and development company. The Company is focused on neuro-pharmaceutical drug development, diagnostics and vaccines. It is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio) pharmaceutical companies by molecular concepts for the applications of psilocybin analogs for overcoming disease. The Company advances pharmaceutical developments through rigorous science and clinical trials while diligently patenting and safeguarding its intellectual property. The Company is engaged in collaborative research with the Michael Smith Laboratories at the University of British Columbia.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-1.05m
  • Incorporated2020
  • Employees--
  • Location
    MYND Life Sciences Inc105-2248 Elgin AvePORT COQUITLAM V3C 2B2CanadaCAN
  • Phone+1 (780) 965-0122
  • Websitehttps://myndsciences.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		 since
announced		Transaction
value
Cava Healthcare IncAnnounced25 Oct 202325 Oct 2023Announced50.00%--
Data delayed at least 15 minutes, as of Jun 24 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.